Response to letter regarding article, "histone deacetylation inhibition in pulmonary hypertension: Therapeutic potential of valproic acid and suberoylanilide hydroxamic acid"

Circulation

Volumn 127, Issue 14, 2013, Pages

  Zhao, Lan ^a   Chen, Chien Nien ^a   Hajji, Nabil ^a   Oliver, Eduardo ^a   Cotroneo, Emanuele ^a   Wharton, John ^a   Wilkins, Martin R ^a   Wang, Daren ^b   Li, Min ^b   Stenmark, Kurt R ^b   McKinsey, Timothy A ^b   Buttrick, Peter ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME INHIBITION; HEART FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HEART RIGHT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; LETTER; LUNG ALVEOLUS CELL; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; HYPERTENSION, PULMONARY; MALE; VALPROIC ACID;

EID: 84876145893     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.154757     Document Type: Letter

References (5)

1. Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR, Wilkins MR. Histone deacet-ylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation. 2012;126:455-467.
2. Cavasin MA, Demos-Davies K, Horn TR, Walker LA, Lemon DD, Birdsey N, Weiser-Evans MC, Harral J, Irwin DC, Anwar A, Yeager ME, Li M, Watson PA, Nemenoff RA, Buttrick PM, Stenmark KR, McKinsey TA. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res. 2012;110:739-748.
3. Bogaard HJ, Mizuno S, Hussaini AA, Toldo S, Abbate A, Kraskauskas D, Kasper M, Natarajan R, Voelkel NF. Suppression of histone deacety-lases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med. 2011;183:1402-1410.
4. McKinsey TA. Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol. 2012;52:303-319.
5. McKinsey TA. Targeting infammation in heart failure with histone deacetylase inhibitors. Mol Med. 2011;17:434-441.